Filing Details
- Accession Number:
- 0001225208-22-006584
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-05 17:52:47
- Reporting Period:
- 2022-05-03
- Accepted Time:
- 2022-05-05 17:52:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1099800 | Edwards Lifesciences Corp | EW | Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) | 364316614 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1438538 | M. Catherine Szyman | One Edwards Way Irvine CA 92614 | Cvp, Critical Care | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-05-03 | 3,775 | $0.00 | 31,344 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2022-05-04 | 23,400 | $21.76 | 54,744 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-05-04 | 493 | $105.93 | 54,251 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2022-05-04 | 3,796 | $105.88 | 50,455 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-04 | 9,155 | $104.18 | 41,300 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-05-04 | 10,449 | $105.10 | 30,851 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Acquire) | Acquisiton | 2022-05-03 | 30,600 | $0.00 | 30,600 | $105.93 |
| Common Stock | Performance Rights | Acquisiton | 2022-05-03 | 4,725 | $0.00 | 4,725 | $0.00 |
| Common Stock | Employee Stock Option (Right to Acquire) | Disposition | 2022-05-04 | 23,400 | $0.00 | 23,400 | $21.76 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,600 | 2023-05-03 | 2029-05-02 | No | 4 | A | Direct |
| 4,725 | 2025-05-03 | No | 4 | A | Direct | |
| 0 | 2016-05-14 | 2022-05-13 | No | 4 | M | Direct |
Footnotes
- These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
- This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
Billionaire Hedge Funds
